Janus kinase 2 (JAK2) is an essential intracellular signal transducer for numerous cytokines and hormones. To examine how JAK2 structural modifications can affect cellular physiology, we created expression vectors for chimeric proteins containing an enhanced green fluorescent protein (EGFP) fused to rat JAK2 (EGFP/rJAK2), and a kinase-inactive variant, EGFP/rJAK2(K882E). The properties of EGFP/rJAK2 were examined following transient transfection of COS-7 cells. EGFP/rJAK2 was expressed throughout the cell, and was found in subcellular membrane, cytosolic and nuclear fractions. Interestingly, EGFP/rJAK2 phosphorylated other proteins in situ without additional cytokine stimulation. Furthermore, despite a much higher level of tyrosine phosphorylation arising from in situ autophosphorylation, the in vitro radiolabelling autokinase activity of EGFP/rJAK2 was significantly less than that of the endogenous JAK2. These results reveal a technical limitation of the application of the ''conventional'' in vitro radiolabelling autokinase assay to hyperphosphorylated forms of the enzyme and illustrate the potential weaknesses in individual assays commonly used to determine JAK2's enzymatic activity and subcellular distribution. We also suggest that the EGFP/rJAK2 model can be very useful in studying JAK2-related cancers, because its ubiquitous distribution and abnormal constitutive hyperphosphorylation may distinguish it from the cytokine-regulated, membrane-proximal form of JAK2 associated with normal physiology.
Introduction
Janus kinase 2 (JAK2) [1, 2] is a member of the Janus protein-tyrosine kinase (JAK) family [3] . Other JAKs found within the phylum Chordata include JAK1 [4] , JAK3 [5, 6] , and TYK2 [7] . Because the JAKs are integral to many aspects of developmental biology and immunology, mutations and regulatory aberrations can have devastating consequences. Several human cancers are associated with constitutive activation of JAK2. Genomic amplification of JAK2 has been observed in Hodgkin's lymphoma [8] . Constitutive activation of JAK2 can arise from overexpression [9] , from loss of feedback regulation [10] , and from chromosomal translocations that displace JAK2's autoinhibitory domain [11, 12] . However, it is improbable that many human diseases arise from congenital systemic inactivation of JAK2 because in transgenic animal models, animals lacking jak2 die in utero due to the inability to progress from primitive to definitive hematopoiesis [13, 14] . There might be other as-yetunrecognized pathologies associated with JAK2 deficiencies in somatic cells, although the nature of such pathologies would be highly speculative.
Despite the broad importance of JAK2, it is still an imperfectly understood enzyme. Surprisingly, even fundamental questions concerning JAK2's subcellular distribution have yet to be resolved in an unambiguous fashion. Because the purified enzyme appears to indiscriminately phosphorylate a variety of substrates [15] , the subcellular localization of the endogenous enzyme would appear to represent an important mechanism for controlling substrate access under physiological conditions. While it is conventional wisdom that JAK2 phosphorylates STATs and other substrates associated with cytokine receptors, one could envision dramatically altered consequences if JAK2 were to directly phosphorylate substrates found within other organelles, such as the nucleus. Some investigators have provided evidence that yellow fluorescent protein-chimeras containing JAK1, JAK2 or TYK2 are predominantly located at the cellular membrane [16, 17] . On the other hand, other groups, whose investigations did not employ fluorescent chimeras, reported a nucleocytoplasmic distribution for JAK2 [18] [19] [20] , while yet other investigators reported that hemagglutinin-tagged JAK2 was distributed in the cytoplasm but excluded from the nucleus [21] . In order to further examine these and other issues surrounding the properties of JAK2's catalytic properties in a cellular context, we sought to develop other approaches to produce the recombinant enzyme in various mammalian cells. To exploit the advantages of fluorescent chimeras in our planned JAK2 structure/function studies, we built an enhanced green fluorescent protein-tagged rat JAK2 protein (EGFP/rJAK2), along with a kinase-inactive EGFP/rJAK2(K882E) variant as a negative control. The enhanced green fluorescent protein (EGFP) was selected for this chimeric protein design because its bright fluorescence easily allows one to track the intracellular localization of the fusion protein in living cells [22] .
Materials and methods

Construction of pEGFP:rJAK2 and pEGFP:rJAK2(K882E) expression vectors
The chimeric pEGFP:rJAK2 expression vector was built in two steps. First, a cDNA fragment encoding the first 295 amino acid residues of rat JAK2 was generated via polymerase chain reaction (PCR) using the plasmid pRA3.17 [23] as a template, and 5¢ATATAAGTACTCAATGG GAATGGCTTGCCTTACAAT3¢ and 5¢TTGA CCACTGAATTCCACCGTTTCCAGTTAT-TA3¢ as the reaction primers. The resultant 0.9 kb PCR product was subcloned into the ScaI/EcoRI site of the pEGFP-C3 vector (Clontech), yielding the plasmid pEGFP:rJAK2(CD295). In the second step, a 3 kb EcoRI fragment encoding the remaining carboxyl terminal of rJAK2 was isolated from pRA3.17, then subcloned into pEGFP:rJAK2(CD295) to yield pEGFP:rJAK2, the structure of which was verified by DNA sequencing. The kinase-inactive pEGFP:rJAK2 (K882E) expression vector was derived from the pEFGP:rJAK2 via QuikCHANGE TM (Stratagene) site-directed mutagenesis using the primers 5¢GAGGTGGTAGCTGTTGAGAAGCTCCAG CACAG3¢ and 5¢CTGTGCTGGAGCTTCT-CAACAGCTACCACCTC3¢. The mutation was confirmed by DNA sequence analysis. Type Culture Collection) were maintained in humidified 5% CO 2 at 37°C in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with L-glutamine, penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (Atlanta Biologicals). COS-7 cells, seeded at a density of 1 Â 10 6 per 100 mm dish, were transiently transfected with 6 lg of plasmid DNA using Effectene TM transfection reagent (Qiagen) according to the manufacturer's instruction. The transfected cells were incubated for 24-72 h before conducting various assays. In case of epifluorescence analysis with 4¢,6-diamidino-2-phenylindole (DAPI) counterstaining, 2 Â 10 4 cells were seeded onto glass cover slips in a 24-well cell culture dish one day before transfection and cells were transiently transfected with 1 lg of plasmid DNA per well.
Cell culture and transfection
COS-7 cells (American
Microscopic and flow cytometry analysis
Three days after transfection, adherent cells were recovered by treatment with sterile trypsin-EDTA (ethylenediamine tetraacetate) solution (Sigma), then washed with phosphate-buffered saline (PBS). After washing, the cells were resuspended in PBS and analyzed for fluorescence intensity by flow cytometry using a fluorescence activated cell sorting (FACS) system (BD Biosciences FACScan system). Fluorescence photomicroscopy was performed using a Leica DM IRB inverted fluorescence microscope equipped with an Optronics MagnaFire digital camera and a filter optimized for GFP fluorescence (480 nm excitation (Ex.) and 535 nm emission with 40 nm and 50 nm respective bandwidths). For epifluorescence analysis with DAPI staining, cells were collected 2 days after transfection, rinsed twice with PBS and fixed by adding 1 ml of 4% paraformaldehyde for 20 min. The cells were washed twice with PBS and stained with 1 nM DAPI for 10 min. The cells on the cover slip were rinsed twice with PBS and mounted on a glass slide and sealed. The cells were observed through an epifluorescence microscope (Nikon EFD-3) at 60 Â magnification with a filter (UV-2 A, Nikon) (Ex. 330-380 nm, DM 400 nm, BA 420 nm) for DAPI staining and another filter (FITC-HVQ, Nikon) (Ex. 460-500 nm, DM 505 nm, BA 510-560 nm) for EGFP and EGFP-chimera proteins.
Immunoprecipitation, SDS-PAGE and Western blot assays
Three days after transfection, 1 Â 10 7 transfected cells were recovered, then lysed in a lysis buffer [24] containing 1% Triton X-100, 5 mM EDTA, 50 mM NaCl, 30 mM sodium diphosphate, 50 mM NaF, 0.2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 5 lg/ml aprotinin, 1 lg/ml pepstatin A, 2 lg/ml leupeptin, and 10 mM Tris-Cl, pH 7.6. After centrifugation (8500 Â g for 15 min at 4°C), the clarified cell lysates were incubated with anti-JAK2 antibodies (cat. # 06-255, Upstate Cell Signaling Solutions) for 3 h at 4°C with mixing, then one-tenth volume of 10% protein-A Sepharose TM CL-4B (Amersham Biosciences) was added and mixed for 2 h at 4°C. The samples were centrifuged at 7000 Â g for 10 min at 4°C to pellet the immobilized JAK2/antibody complexes, which were washed three times with lysis buffer. The sample was divided into two equal aliquots, one of which was analyzed by Western blot and the other was analyzed by in vitro radiolabelling autokinase assay, as previously described [25] . For the Western blot analysis, the immunoprecipitated materials were resolved by 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), then transferred to Immobilon-P transfer membranes (Millipore). The membranes were probed with either anti-JAK2, anti-phosphotyrosine (4G10, cat. # 05-321, Upstate Cell Signaling Solutions) or anti-GFP antibody (cat. # 8367-1, Clontech), thrice washed, re-blocked, probed with appropriate secondary antibodies, and thrice washed again. The immunoreactive proteins were detected using the enhanced chemiluminescence system (ECL, Amersham Biosciences). For reprobing with a different antibody, previously probed membrane was incubated with buffer containing 100 mM b-mercaptoethanol, 2% SDS, and 62.5 mM Tris-Cl (pH 6.7) for 30 min at 50°C. After being washed and blocked, the membrane was reprobed and processed as described above.
In vitro radiolabelling autokinase assay
The samples were prepared as described in the ''Immunoprecipitation, SDS-PAGE and Western blot assays'' section. The second half of the immunoprecipitated pellet was pre-treated with 10 mM dithiothreitol (DTT) to maximize enzyme activity [25] , resuspended with 100 ll of autokinase cocktail solution (250 lCi/ml carrier-free [c 32 P]ATP, 50 mM NaCl, 5 mM MgCl 2 , 5 mM MnCl 2 , 0.1 mM Na 3 VO 4 , 10 mM HEPES, pH 7.6) and incubated at room temperature for 20 min with mixing. The reactions were stopped by centrifuging briefly, discarding the cocktail solution and washing the pellets three times with lysis buffer. The samples were then boiled with SDS-PAGE sample buffer for 3 min, and resolved by 7.5% SDS-PAGE. The gel was transblotted onto Immobilon-P transfer membranes and Coomassie stained; radiolabel incorporation was quantified via PhosphorImager analysis (Molecular Dynamics) [15] .
Subcellular fractionation
Cell fractions were prepared as previously described by Behrmann et al. [16] . In brief, 2 days after transfection, 5 Â 10 6 cells were harvested and resuspended in 1 ml of hypotonic lysis buffer (10 mM NaCl, 3 mM MgCl 2 , 1 mM sodium vanadate, 5 lg/ml aprotinin, 3 lg/ml pepstatin, 5 lg/ml leupeptin, 1 mM EDTA, 1 mM DTT, and 10 mM Tris-Cl, pH 7.5). After homogenation using a Dounce homogenizer, the nuclei were separated by centrifugation (35 Â g, 15 min, twice), yielding the crude nuclear pellet. Centrifugation of this supernatant at 12,500 Â g for 15 min generated another supernatant (the crude cytoplasmic fraction) and pellet (the crude plasma membrane fraction). The crude cytoplasmic fraction was further centrifuged for 1 h at 100,000 Â g to yield the pure cytoplasmic fraction. The crude membrane pellet was resuspended and lysed in 1 ml of 1% Triton lysis buffer (1% Triton X-100, 120 mM NaCl, 10 mM NaF, 1 mM sodium vanadate, 5 lg/ml aprotinin, 3 lg/ml pepstatin, 5 lg/ml leupeptin, 1 mM EDTA, 1 mM DTT, and 20 mM Tris-Cl, pH 7.5). After 30-min incubation, the lysate was centrifuged at 12,500 Â g for 15 min to remove insoluble material and the supernatant was used as the pure membrane fraction. Nuclear fractions were prepared as described by Buckley et al. [26] with a slight modification. The crude nuclear pellet was resuspended in 1 ml of nuclear isolation buffer (0.5% Nonidet P-40, 10 mM NaCl, 3 mM MgCl 2 , 1 mM sodium vanadate, 5 lg/ml aprotinin, 3 lg/ml pepstatin, 5 lg/ml leupeptin, 1 mM EDTA, 1 mM DTT, and 10 mM Tris-Cl, pH 7.5), incubated on ice for 5 min, then centrifuged at 35 Â g twice. The pellet was washed with 1 ml of 2% Triton-containing nuclear lysis buffer (2% Triton X-100, 280 mM NaCl, 10 mM NaF, 1 mM sodium vanadate, 5 lg/ ml aprotinin, 3 lg/ml pepstatin, 5 lg/ml leupeptin, 1 mM EDTA, 1 mM DTT, and 20 mM Tris-Cl, pH 7.5), and centrifuged at 12,500 Â g for 10 min. The purified nuclear pellet was solubilized in 200 ll of SDS-PAGE sample buffer.
Western blot assay for subcellular fractions
Fifty microliters of each fraction (50 ll from 1 ml of membrane fraction, 50 ll from 1 ml of cystosol fraction, and 50 ll from 200 ll of nuclear fraction) were electrophoresed via SDS-PAGE prior to Western blot assay. The proteins were transferred to Immobilon-P transfer membranes and probed with the following antibodies: anti-JAK2, antilamin A/C (cat. # 636, Santa Cruz Biotechnology), anti-calnexin (cat. # 610523, Transduction Laboratories), anti-phosphotyrosine, anti-GFP, and anti-phospho-JAK2 (pTyr-1007,1008; cat. # 07-123, Upstate Cell Signaling Solutions). Proteins were visualized using the ECL system.
Statistical analysis
To compare the relative fluorescence intensity of chimeric protein expressing cells, one way ANO-VA and Student-Newman-Keuls post-hoc test were used. Significance was defined as p < 0.05.
All experiments were repeated at least three times and representative images are shown.
Results
Microscopic examination of COS-7 cells producing recombinant EGFP, EGFP/rJAK2, and EGFP/ rJAK2(K882E) proteins
We created expression vectors for an enhanced green fluorescent protein chimera in which the fluorescent protein was fused to the amino-terminus of rat JAK2 (EGFP/rJAK2), along with a kinase-inactive control protein (EGFP/ rJAK2(K882E)) [27, 28] . Following transient transfection, all three fluorescent chimeric proteins were produced in COS-7 cells and the characteristic green fluorescence was observed microscopically for all recombinant proteins (Figure 1 ). The fluorescence appeared to be uniformly distributed throughout the cells for all three constructs and cells could be found with uniform patterns that did not appear to vary according to the nature of the chimera. We also observed that COS-7 cells producing either EGFP/rJAK2 or EGFP/ rJAK2(K882E) were less bright than COS-7 cells producing non-chimeric EGFP. Furthermore, the fluorescent cells which expressed recombinant JAK2 contracted into a non-viable spheroid which ultimately detached from the surface of the culture dish. We were unsuccessful in attempts to establish stably transfected COS-7 cells or CHO-K1 cells producing either EGFP/rJAK2 or EGFP/ rJAK2(K882E) using G418 drug selection and physical isolation by ring cloning, although we were able to isolate apparently stable clonal cells lines producing the non-chimeric EGFP (data not shown).
To examine subcellular distribution, the transiently transfected COS-7 cells were fixed, counterstained with DAPI to reveal nuclei, then examined at 60 Â magnification using an upright epifluorescence microscope (Nikon EFD-3). Consistently, the EGFP/rJAK2 was ubiquitously distributed throughout the transfected COS-7 cells, as was the case with the non-tagged EGFP (Figure 2 ). Interestingly, EGFP/rJAK2(K882E) was excluded from the nucleus in some cells, as shown in an example in Figure 2 (pattern A), but was uniformly distributed in other transfected cells in the same experiments (pattern B).
Subcellular fractionation of transfected COS-7 cells
pEGFP:rJAK2 transfected COS-7 cells were carefully lysed and prepared for subcellular fractionation. Sham-transfected COS-7 cells were also prepared as a control. The lysed cells were fractionated as described under the ''Materials and methods'' section and the fractionated samples were resolved via SDS-PAGE, transferred to membranes and analyzed by Western blot. To ensure that the purified membrane, cytosolic and nuclear fractions were not contaminated by each other, the membranes were probed with antibodies for calnexin, a membrane fraction marker [29, 30] , and for lamins A and C, which are nuclear marker proteins [31, 32] . The membranes were stripped, then re-probed with antibodies recognizing JAK2, GFP, phosphotyrosine or phospho-JAK2. The results are shown in Figure 3 .
The combined presence of lamins A and C only in the nuclear fractions (Figure 3 , panel F, lanes 3 and 6) and of calnexin only in the membrane fractions ( Figure 3, panel E, lanes 1 and 4) indicates that the three subcellular fractions were adequately purified. The detection of a common 158 kDa protein by antibodies recognizing JAK2 ( Figure 3, panel A, lanes 4, 5 and 6 ) and GFP ( Figure 3, panel B, lanes 4, 5 and 6) shows that the EGFP/rJAK2 chimera was clearly present in all compartments including membrane fraction, cytosol fraction and nuclear fraction. Further, the EGFP/rJAK2 proteins in all compartments contained phosphorylated tyrosine residues (Figure 3 , panel C, lanes 4, 5 and 6), which included tyrosine phosphorylation within the activation loop (Figure 3, panel D, lanes 4, 5 and 6 ). The nuclear population of EGFP/rJAK2 apparently contained a greater proportion of phosphotyrosine than the other two populations, but this has not yet been verified by alternative methodologies. In this experiment, the endogenous JAK2 was most clearly detected in the cytosol and nuclear fractions ( Figure 3, panel A, lanes 2, 3, 5 and 6 ).
We also compared the subcellular distribution of EGFP/rJAK2 in pEGFP:rJAK2-transfected COS-7 cells with that of the inactive kinase in pEGFP:rJAK2(K882E)-transfected COS-7 cells (Figure 4) . Again, the fraction markers indicated that the three subcellular fractions were appropriately purified (panel E and F). The detection of a common 158 kDa protein by anti-JAK2 antibody and anti-GFP antibody showed that EGFP/ rJAK2 proteins (Figure 4, panel A and B, lanes  1, 2 and 3 ) and EGFP/rJAK2(K882E) proteins The EGFP/rJAK2 proteins in all compartments were tyrosine-phosphorylated (Figure 4,  panel C, lanes 1, 2 and 3) , whereas the EGFP/ rJAK2(K882E) proteins showed no sign of tyrosine phosphorylation (Figure 4, panel C, lanes 4, 5  and 6 ). As expected, the EGFP/rJAK2(K882E) proteins also lacked tyrosine phosphorylation within the activation loop (Figure 4 , panel D, lanes 4, 5 and 6), in contrast to the EGFP/rJAK2 proteins ( Figure 4, panel C, lanes 1, 2 and 3) .
The results of the subcellular fractionation experiments (Figures 3 and 4) corroborated the microscopy evidence (Figures 1 and 2) indicating that the EGFP/rJAK2 is ubiquitously distributed throughout the transfected COS-7 cells. Further, the ubiquitous distribution pattern appears to be completely independent of the presence or absence of kinase activity.
FACS analysis of EGFP/rJAK2 fusion proteins
Fluorescence microscopy indicated that the fluorescence intensity of EGFP was greater than that of EGFP/rJAK2 and EGFP/rJAK2(K882E). To confirm this, we examined the fluorescence intensity of transiently transfected COS-7 cells using fluorescence activated cell sorting. Sample fluorescence distribution profiles of sham-transfected, pEGFP-transfected, pEGFP:rJAK2-transfected and pEGFP:rJAK2(K882E)-transfected COS-7 cells are shown in Figure 5 , panel A. Analysis of these distribution profiles showed that there were no differences in transfection efficiency due to differences between the expression vectors. The geometric mean values of the relative fluorescence intensities of the fluorescent transfected cells are plotted in Figure 5, 
Characteristics of the EGFP/rJAK2 chimeras produced in COS-7 cells
Transiently transfected COS-7 cells were lysed with buffer containing nonionic detergent and the recombinant proteins were recovered via immunoprecipitation with polyclonal antibodies that recognized JAK2, which also recovered the endogenous enzyme as an internal control. The EGFP/ rJAK2 fusion proteins produced in COS-7 cells migrated under SDS-PAGE conditions as anticipated based on their predicted molecular mass of 158 kDa, and they were recognized by anti-JAK2 and anti-GFP antibodies, as shown in Figure 6 , panels A and B, respectively. Densitometric analysis of the Western blots showed that EGFP/ rJAK2 and EGFP/rJAK2(K882E) were produced at approximately equal levels.
However, Western blot analysis using antiphosphotyrosine antibodies revealed a dramatic difference in the tyrosine phosphorylation status of these chimeric proteins. EGFP/rJAK2 alone exhibited significant tyrosine phosphorylation and the tyrosine phosphorylation did not require explicit cytokine receptor stimulation ( Figure 6 , panel C). The lack of tyrosine phosphorylation of the kinase-inactive EGFP/rJAK2(K882E) chimera provides support for the interpretation that the phosphorylation of tyrosines in EGFP/rJAK2 arose from an autophosphorylation event, rather than due to a trans-phosphorylation by another protein-tyrosine kinase present in COS-7 cells. We did not detect any significant level of phosphotyrosine in the endogenous JAK2 protein.
Aliquots of the anti-JAK2 immunoprecipitated material were then subjected to in vitro radiolabelling autokinase assays, which provide a basic measure of JAK2's enzymatic activity [33] [34] [35] . No detectable activity was associated with the kinaseinactive EGFP/rJAK2(K882E), as anticipated. While EGFP/rJAK2 exhibited autokinase activity, it was very low in comparison to that of the endogenous JAK2 ( Figure 6, panel D) . When the autokinase signal intensities were normalized to those of the JAK2-cross-reactive signals ( Figure 6 , panel A), the autokinase activity of EGFP/rJAK2 was only 0.7% of the normalized autokinase activity of the endogenous JAK2.
In order to verify that EGFP/rJAK2 could transphosphorylate other cellular components, as one would expect of a functional kinase, we analyzed the phosphotyrosine content of the transfected cell lysates. As shown (Figure 7 , panel A, lane J), the crude lysate from COS-7 cells producing EGFP/rJAK2 contained a broad range of tyrosine-phosphorylated proteins that were not (Figure 7, panel  B) . This result confirms that the EGFP/rJAK2 chimera had the capacity to function as both an autokinase and an exokinase without the need for explicit cytokine stimulation.
Discussion
Applications of fluorescent protein technology have made a profound and revolutionary impact in biology [36] . Derivatives of the green fluorescent protein cloned from Aequora victoria have been used extensively in biological research based on the assumption that it does not significantly alter the function of its fusion partner [37, 38] . Yet there are occasional reports of functional changes arising in proteins as a consequence of the relative placement of the GFP fusion partner [39, 40] . When we began this study of EGFP-fused JAK2 chimeras, we noticed a change in the fluorescence intensities of the chimeric fluorescent proteins. Our concern that the presence of the fluorescent fusion partner may have reciprocally altered the properties of the JAK2 domain led us to closely examine other properties of the EGFP/rJAK2 chimeras produced in COS-7 cells. Two important observations, which we will now discuss, emerged from the experiments which ensued.
Characteristics of the EGFP/rJAK2 chimeras produced in COS-7 cells
Western blot analyses using anti-GFP and anti-JAK2 antibodies showed that EGFP/rJAK2 and EGFP/rJAK2(K882E) were expressed at approximately equal levels in COS-7 cells, and that the recombinant JAK2 forms were produced at a much higher level than the endogenous JAK2 ( Figure 6 ). Western blot analysis using antiphosphotyrosine antibodies revealed that only EGFP/rJAK2 exhibited significant tyrosine phosphorylation in situ ( Figure 6, panel C) . We interpret the constitutive activation of EGFP/ rJAK2 as an apparent consequence of overexpression, as its tyrosine autophosphorylation did not require explicit cytokine receptor stimulation. Corroborating evidence for constitutive EGFP/ rJAK2 activation was observed in the in situ transphosphorylation of various cellular proteins ( Figure 7, panel A) . Although a significant level of in situ tyrosine autophosphorylation was not observed in the endogenous JAK2 protein, it possessed a significantly higher level of normalized in vitro radiolabelling autokinase activity than did the EGFP/rJAK2. The endogenous JAK2 may have contained a sufficient, albeit undetectable, level of tyrosine phosphorylation within the activation loop so that it could efficiently autophosphorylate under in vitro assay conditions [41] .
The apparent low level of EGFP/rJAK2's in vitro activity was a surprising result. Typically, the tyrosine phosphorylation status of JAK2 correlates positively with the incorporation of radioactive phosphate in the in vitro radiolabelling autokinase assay. While it is possible that the presence of the EGFP fusion partner may have perturbed the enzymatic properties of the JAK2 domain, we would like to suggest another interpretation. A simple and plausible explanation for our unexpected observation might be that hyperphosphorylation of the chimeric EGFP/rJAK2 in situ resulted in a relative paucity of available free tyrosine sites for subsequent in vitro autophosphorylation. Our laboratory is more rigorously evaluating this explanation for the unexpected discordance between in situ hyperphosphorylation and in vitro hypophosphorylation when certain recombinant JAK2 variants are assayed (Lee, Chatti and Duhe, unpublished results).
Subcellular localizations of EGFP/rJAK2 and EGFP/rJAK2(K882E)
To determine the subcellular distribution of the recombinant proteins, the transiently transfected COS-7 cells were examined via epifluorescence microscopy after DAPI counterstaining. Consistently, the EGFP/rJAK2 was ubiquitously distributed throughout the transfected COS-7 cells, as was the case with the non-tagged EGFP (Figure 2) . Interestingly, EGFP/rJAK2(K882E) was excluded from the nucleus in some cells, but was uniformly distributed in other transfected cells in the same experiments (compare Figure 2 , patterns A vs. B).
These observations are noteworthy because, while various groups employing a variety of approaches to determine the subcellular localization of JAKs have provided apparently conflicting conclusions [16, 18, 20, 21] , reports of ubiquitous distribution are rare. To our knowledge, the observation that a single JAK isoform can either be located in or excluded from the nucleus under identical experimental conditions has not been previously reported.
The current controversy surrounding the subcellular localization of JAKs [16, 18, 20, 21, 42, 43] arose in part from differences in experimental methodologies (e.g., immunohistochemistry vs. chimeric fluorescent protein expression) and in reagent selection (e.g., different cell lines). There is a reasonable expectation to find evidence for the membrane localization of JAK2, because as one group correctly stated, ''all functional features of JAK proteins point to their involvement in events occurring at the cell surface or at intracellular membranes'' [16] . However, one must remain open to other scenarios, as exemplified by the recognition that the epidermal growth factor receptor (EGFR) protein-tyrosine kinase, long established as a transmembrane transducer of extracellular signals, can upregulate cyclin D1 when EGFR is localized to the nucleus [44] . Because a nuclear localization sequence has been identified in JAK2 [20] , perhaps the empirical evidence underlying contemporary dogma should be reconsidered. For example, co-immunoprecipitation experiments helped establish the physical association between JAKs and the intracellular domains of cytokine receptors. In those experiments non-ionic detergent solubilization or mechanical disruption was used to lyse the cells, followed by sedimentation of insoluble materials, which would have removed the nuclear components from further examination. Further, one must acknowledge that many, if not most, commercial antibodies recognizing JAK2 will apparently cross-react with other proteins and are hence unsuitable for immunohistochemical studies. Therefore, the subcellular localization of the chimeric JAK2 should be examined cautiously with multiple methodologies to compensate for artifacts. We employed subcellular fractionation techniques to confirm that the EGFP/rJAK2 chimera was clearly present in membrane, cytosol and nuclear fractions. The EGFP/rJAK2 proteins in all compartments contained phosphorylated tyrosine residues (Figure 3 Figure 4, panel D, lanes 1, 2 and 3) . In contrast, neither the endogenous JAK2 (Figure 3 ) nor the inactive EGFP/rJAK2(K882E) (Figure 4 , panel C and D, lanes 4, 5, and 6) exhibited any sign of tyrosine phosphorylation.
We were somewhat surprised that the endogenous JAK2 was so clearly detected in the cytosol and nuclear fractions (Figure 3 , panel A, lanes 2, 3, 5 and 6). Endogenous JAK2 could be detected in the membrane fraction when adequate amounts of protein were analyzed (Figure 4, panel A, lanes 1  and 4) . Taken together, the results of the subcellular fractionation experiments (Figure 3 and 4) and the microscopy evidence (Figures 1 and 2) indicate that the EGFP/rJAK2 is ubiquitously distributed throughout the transfected COS-7 cells.
The nuclear localization of JAK2, which has been reported with variable consistency from one lab to another, may have physiological significance and should therefore be carefully scrutinized. The signal transduction pathways related to receptor-associated JAK2 activation have been well-characterized and are now accepted as dogma. If JAK2 is exclusively associated with the membrane, then one would expect that overexpression of JAK2 might simply increase classical receptor-associated signal transduction throughput. However, because we have previously noted that JAK2's substrate recognition is promiscuous [15] , then we predict that the subcellular distribution of active JAK2 would significantly alter the pattern of JAK2-catalyzed substrate phosphorylation. If it is true that active JAK2 is present in the nucleus under certain conditions, then the resultant pattern of substrate phosphorylation would be radically different from the classical receptorassociated pattern. This may be of particular importance in studying the mechanism of JAK2-mediated neoplastic transformation, which is a subject of great interest and of many ongoing investigations.
